{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:56:26Z","timestamp":1787784986364,"version":"build-2784847793"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T00:00:00Z","timestamp":1322524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1038\/nrrheum.2011.181","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T11:51:55Z","timestamp":1322567515000},"page":"90-96","source":"Crossref","is-referenced-by-count":137,"title":["Epidemiology and pathogenesis of osteonecrosis of the jaw"],"prefix":"10.1038","volume":"8","author":[{"given":"Ian R.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,29]]},"reference":[{"key":"BFnrrheum2011181_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61, 1115\u20131117 (2003).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62, 527\u2013534 (2004).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla, S. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22, 1479\u20131491 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum2011181_CR4","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65, 369\u2013376 (2007).","DOI":"10.1016\/j.joms.2006.11.003"},{"issue":"5 Suppl.","key":"BFnrrheum2011181_CR5","first-page":"2","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J. Oral Maxillofac. Surg. 67 (5 Suppl.), 2\u201312 (2009).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125\u20131132 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum2011181_CR7","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132\u20135139 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum2011181_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813\u2013822 (2011).","journal-title":"Lancet"},{"key":"BFnrrheum2011181_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele, S. et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am. J. Med. 123, 1060\u20131064 (2010).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2011181_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","volume":"136","author":"O Filleul","year":"2010","unstructured":"Filleul, O., Crompot, E. & Saussez, S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J. Cancer Res. Clin. Oncol. 136, 1117\u20131124 (2010).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFnrrheum2011181_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","volume":"36","author":"MH Abu-Id","year":"2008","unstructured":"Abu-Id, M. H. et al. \u201cBis-phossy jaws\u201d\u2014high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J. Craniomaxillofac. Surg. 36, 95\u2013103 (2008).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"BFnrrheum2011181_CR12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson, G. S., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J. Nat. Cancer Inst. 99, 1016\u20131024 (2007).","journal-title":"J. Nat. Cancer Inst."},{"key":"BFnrrheum2011181_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","volume":"14","author":"PK Palaska","year":"2009","unstructured":"Palaska, P. K., Cartsos, V. & Zavras, A. I. Bisphosphonates and time to osteonecrosis development. Oncologist 14, 1154\u20131166 (2009).","journal-title":"Oncologist"},{"key":"BFnrrheum2011181_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie, B. G., Katz, M. & Crowley, J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353, 99\u2013102 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011181_CR15","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos, K. et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 27, 5356\u20135362 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum2011181_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","volume":"66","author":"JH Wessel","year":"2008","unstructured":"Wessel, J. H., Dodson, T. B. & Zavras, A. I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case\u2013control study. J. Oral Maxillofac. Surg. 66, 625\u2013631 (2008).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","volume":"68","author":"G Saia","year":"2010","unstructured":"Saia, G. et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J. Oral Maxillofac. Surg. 68, 797\u2013804 (2010).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","volume":"47","author":"P Vescovi","year":"2011","unstructured":"Vescovi, P. et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 47, 191\u2013194 (2011).","journal-title":"Oral Oncol."},{"key":"BFnrrheum2011181_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00198-007-0384-2","volume":"18","author":"N Yarom","year":"2007","unstructured":"Yarom, N. et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos. Int. 18, 1363\u20131370 (2007).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum2011181_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijom.2010.11.002","volume":"40","author":"M Manfredi","year":"2011","unstructured":"Manfredi, M., Merigo, E., Guidotti, R., Meleti, M. & Vescovi, P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int. J. Oral Maxillofac. Surg. 40, 277\u2013284 (2011).","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"A Barasch","year":"2011","unstructured":"Barasch, A. et al. Risk factors for osteonecrosis of the jaws: a case\u2013control study from the CONDOR dental PBRN. J. Dent. Res. 90, 439\u2013444 (2011).","journal-title":"J. Dent. Res."},{"key":"BFnrrheum2011181_CR22","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","volume":"141","author":"JT Grbic","year":"2010","unstructured":"Grbic, J. T. et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J. Amer. Dent. Ass. 141, 1365\u20131370 (2010).","journal-title":"J. Amer. Dent. Ass."},{"key":"BFnrrheum2011181_CR23","first-page":"S91","volume":"48","author":"DM Black","year":"2011","unstructured":"Black, D. M. et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON\u2013Pivotal Fracture Trial (PFT). Bone 48, S91 (2011).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","volume":"139","author":"VM Cartsos","year":"2008","unstructured":"Cartsos, V. M., Zhu, S. & Zavras, A. I. Bisphosphonate use and the risk of adverse jaw outcomes. J. Amer. Dent. Ass. 139, 23\u201330 (2008).","journal-title":"J. Amer. Dent. Ass."},{"key":"BFnrrheum2011181_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","volume":"19","author":"M Pazianas","year":"2008","unstructured":"Pazianas, M., Blumentals, W. A. & Miller, P. D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos. Int. 19, 773\u2013779 (2008).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum2011181_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo, J. C. et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J. Oral Maxillofac. Surg. 68, 243\u2013253 (2010).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00256-008-0549-x","volume":"38","author":"IR Reid","year":"2009","unstructured":"Reid, I. R. & Cundy, T. Osteonecrosis of the jaw. Skeletal Radiol. 38, 5\u20139 (2009).","journal-title":"Skeletal Radiol."},{"key":"BFnrrheum2011181_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid, I. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898\u2013908 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011181_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1359\/jbmr.090709","volume":"25","author":"AL Langston","year":"2009","unstructured":"Langston, A. L. et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J. Bone Miner. Res. 25, 20\u201331 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum2011181_CR30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/jbmr.438","volume":"26","author":"IR Reid","year":"2011","unstructured":"Reid, I. R. et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J. Bone Miner. Res. 26, 2261\u20132270 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum2011181_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1600-0714.2007.00607.x","volume":"37","author":"B Malmgren","year":"2008","unstructured":"Malmgren, B., Atrom, E. & Soderhall, S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J. Oral Pathol. Med. 37, 196\u2013200 (2008).","journal-title":"J. Oral Pathol. Med."},{"key":"BFnrrheum2011181_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","volume":"139","author":"JT Grbic","year":"2008","unstructured":"Grbic, J. T. et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J. Amer. Dent. Ass. 139, 32\u201340 (2008).","journal-title":"J. Amer. Dent. Ass."},{"key":"BFnrrheum2011181_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.joms.2009.01.003","volume":"67","author":"LA Assael","year":"2009","unstructured":"Assael, L. A. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J. Oral Maxillofac. Surg. 67, 35\u201343 (2009).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","volume":"35","author":"T Hansen","year":"2006","unstructured":"Hansen, T., Kunkel, M., Weber, A. & Kirkpatrick, C. J. Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral Pathol. Med. 35, 155\u2013160 (2006).","journal-title":"J. Oral Pathol. Med."},{"key":"BFnrrheum2011181_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3109\/01913121003729806","volume":"34","author":"I Perrotta","year":"2010","unstructured":"Perrotta, I. et al. Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study. Ultrastruct. Path. 34, 207\u2013213 (2010).","journal-title":"Ultrastruct. Path."},{"key":"BFnrrheum2011181_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bone.2009.05.008","volume":"45","author":"G Favia","year":"2009","unstructured":"Favia, G., Pilolli, G. P. & Maiorano, E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45, 406\u2013413 (2009).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","volume":"140","author":"PP Sedghizadeh","year":"2009","unstructured":"Sedghizadeh, P. P. et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J. Amer. Dent. Ass. 140, 1259\u20131265 (2009).","journal-title":"J. Amer. Dent. Ass."},{"key":"BFnrrheum2011181_CR38","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00428-007-0516-2","volume":"451","author":"T Hansen","year":"2007","unstructured":"Hansen, T. et al. Actinomycosis of the jaws\u2014histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 451, 1009\u20131017 (2007).","journal-title":"Virchows Arch."},{"key":"BFnrrheum2011181_CR39","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/IAI.64.7.2371-2380.1996","volume":"64","author":"SP Nair","year":"1996","unstructured":"Nair, S. P. et al. Bacterially induced bone destruction: mechanisms and misconceptions. Infect. Immun. 64, 2371\u20132380 (1996).","journal-title":"Infect. Immun."},{"key":"BFnrrheum2011181_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.micpath.2007.03.001","volume":"43","author":"GN Belibasakis","year":"2007","unstructured":"Belibasakis, G. N. et al. Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb. Pathog. 43, 46\u201353 (2007).","journal-title":"Microb. Pathog."},{"key":"BFnrrheum2011181_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.micpath.2010.11.002","volume":"50","author":"GN Belibasakis","year":"2011","unstructured":"Belibasakis, G. N., Meier, A., Guggenheim, B. & Bostanci, N. Oral biofilm challenge regulates the RANKL\u2013OPG system in periodontal ligament and dental pulp cells. Microb. Pathog. 50, 6\u201311 (2011).","journal-title":"Microb. Pathog."},{"key":"BFnrrheum2011181_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1399-302X.2008.00494.x","volume":"24","author":"X Han","year":"2009","unstructured":"Han, X. et al. Expression of receptor activator of nuclear factor-\u03baB ligand by B cells in response to oral bacteria. Oral Microbiol. Immunol. 24, 190\u2013196 (2009).","journal-title":"Oral Microbiol. Immunol."},{"key":"BFnrrheum2011181_CR43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","volume":"41","author":"IR Reid","year":"2007","unstructured":"Reid, I. R., Bolland, M. J. & Grey, A. B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41, 318\u2013320 (2007).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","volume":"44","author":"IR Reid","year":"2009","unstructured":"Reid, I. R. Osteonecrosis of the jaw: who gets it, and why? Bone 44, 4\u201310 (2009).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","volume":"42","author":"FP Coxon","year":"2008","unstructured":"Coxon, F. P., Thompson, K., Roelofs, A. J., Ebetino, F. H. & Rogers, M. J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42, 848\u2013860 (2008).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bone.2011.07.020","volume":"49","author":"J Cornish","year":"2011","unstructured":"Cornish, J. et al. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 49, 710\u2013716 (2011).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR47","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989\u20131999 (2010).","journal-title":"Lancet"},{"key":"BFnrrheum2011181_CR48","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors study group. J. Clin. Oncol. 21, 3150\u20133157 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum2011181_CR49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson, J. R. et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases\u2014a double-blind, randomized dose-response study. Cancer 91, 1191\u20131200 (2001).","journal-title":"Cancer"},{"key":"BFnrrheum2011181_CR50","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen, L. S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7, 377\u2013387 (2001).","journal-title":"Cancer J."},{"key":"BFnrrheum2011181_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jnci\/djq516","volume":"103","author":"M Pazianas","year":"2011","unstructured":"Pazianas, M. Osteonecrosis of the jaw and the role of macrophages. J. Nat. Cancer Inst. 103, 232\u2013240 (2011).","journal-title":"J. Nat. Cancer Inst."},{"key":"BFnrrheum2011181_CR52","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"Ferrari-Lacraz, S. & Ferrari, S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22, 435\u2013446 (2011).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum2011181_CR53","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/nm1518","volume":"12","author":"K Loser","year":"2006","unstructured":"Loser, K. et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12, 1372\u20131379 (2006).","journal-title":"Nat. Med."},{"key":"BFnrrheum2011181_CR54","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011181_CR55","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","volume":"21","author":"KA Toulis","year":"2010","unstructured":"Toulis, K. A. & Anastasilakis, A. D. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos. Int. 21, 1963\u20131964 (2010).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum2011181_CR56","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bone.2009.09.026","volume":"46","author":"A Kyrgidis","year":"2010","unstructured":"Kyrgidis, A. & Verrou, E. Fatigue in bone: a novel phenomenon attributable to bisphosphonate use. Bone 46, 556 (2010).","journal-title":"Bone"},{"key":"BFnrrheum2011181_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","volume":"65","author":"RP Harper","year":"2007","unstructured":"Harper, R. P. & Fung, E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]. J. Oral Maxillofac. Surg. 65, 573\u2013580 (2007).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR58","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMc1002684","volume":"363","author":"A Cheung","year":"2010","unstructured":"Cheung, A. & Seeman, E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N. Engl. J. Med. 363, 2473\u20132474 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011181_CR59","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.081176","volume":"36","author":"AN Lau","year":"2009","unstructured":"Lau, A. N. & Adachi, J. D. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1\u201334)] therapy. J. Rheumatol. 36, 1835\u20131837 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011181_CR60","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid, I. R. et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res. 25, 2256\u20132265 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum2011181_CR61","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1056\/NEJMcpc0800341","volume":"358","author":"TB Dodson","year":"2008","unstructured":"Dodson, T. B. et al. A woman with a nonhealing ulcer of the jaw\u2014gingival ulceration, inflammation, and acute osteomyelitis with actinomyces, all associated with necrosis of bone (bisphosphonate-related osteonecrosis of bone). N. Engl. J. Med. 358, 1283\u20131291 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2011181_CR62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/RCT.0b013e31817e4986","volume":"33","author":"A Krishnan","year":"2009","unstructured":"Krishnan, A., Arslanoglu, A., Yildirm, N., Silbergleit, R. & Aygun, N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J. Comput. Assist. Tomogr. 33, 298\u2013304 (2009).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"BFnrrheum2011181_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242\u2013251 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum2011181_CR64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3899\/jrheum.080759","volume":"36","author":"AA Khan","year":"2009","unstructured":"Khan, A. A. et al. Bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 36, 478\u2013490 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2011181_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2008","unstructured":"Ripamonti, C. I. et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20, 137\u2013145 (2008).","journal-title":"Ann. Oncol."},{"key":"BFnrrheum2011181_CR66","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","volume":"21","author":"A Corso","year":"2007","unstructured":"Corso, A. et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21, 1545\u20131548 (2007).","journal-title":"Leukemia"},{"key":"BFnrrheum2011181_CR67","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","volume":"11","author":"P Gimsing","year":"2010","unstructured":"Gimsing, P. et al. Effect of pamidronate 30\u00a0mg versus 90\u00a0mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 11, 973\u2013982 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrrheum2011181_CR68","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","volume":"137","author":"T Mucke","year":"2011","unstructured":"Mucke, T. et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J. Cancer Res. Clin. Oncol. 137, 907\u2013913 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFnrrheum2011181_CR69","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.joms.2010.06.200","volume":"69","author":"S Hoefert","year":"2011","unstructured":"Hoefert, S. & Eufinger, H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J. Oral Maxillofac. Surg. 69, 362\u2013380 (2011).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2011181_CR70","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.joms.2007.11.035","volume":"66","author":"PP Sedghizadeh","year":"2008","unstructured":"Sedghizadeh, P. P. et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J. Oral Maxillofac. Surg. 66, 767\u2013775 (2008).","journal-title":"J. Oral Maxillofac. Surg."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.181","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:28:37Z","timestamp":1684470517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,29]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["BFnrrheum2011181"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2011.181","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,29]]}}}